Urolithin and Ginseng Combination for Mitochondrial Function
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions related to inadequate mitochondrial activity, such as obesity, metabolic syndrome, and neurodegenerative diseases, are not fully effective in enhancing mitochondrial function and reducing inflammatory and oxidative stress.
Innovation Solution
Combining urolithins with ginseng-derived compounds or ginseng extracts, and/or notoginseng-derived compounds or notoginseng extracts, to create compositions that modulate different biochemical pathways, leading to synergistic effects in enhancing mitochondrial function and reducing inflammation and oxidative stress.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If single urolithin compounds are used to treat mitochondrial conditions, then some therapeutic effect is achieved, but the effectiveness is insufficient and multiple conditions require multiple different urolithins
Solution Approach 1:
The patent combines multiple urolithin compounds (urolithin A, B, C, D) into a single composite formulation that can address multiple mitochondrial conditions simultaneously. This merging approach allows one treatment to cover obesity, metabolic syndrome, neurodegenerative diseases, and other mitochondrial dysfunction conditions, reducing the need for multiple separate compounds while maintaining comprehensive therapeutic effectiveness.
Solution Approach 2:
The composite urolithin formulation is designed to serve multiple functions across different disease states. The combination of urolithins A, B, C, and D provides universal therapeutic activity that can be applied to various mitochondrial conditions including metabolic disorders, neurodegenerative diseases, cardiovascular conditions, and aging-related mitochondrial dysfunction, making a single formulation applicable to many different therapeutic scenarios.
2Adaptability or versatility
If multiple different urolithin compounds are used to treat different conditions, then comprehensive coverage is achieved, but the complexity of treatment regimens increases
Solution Approach 1:
The patent merges multiple urolithin compounds into a single composite formulation that maintains comprehensive coverage across different conditions. By combining urolithins A, B, C, and D in one formulation, the patent eliminates the need for patients to take multiple separate compounds for different conditions, thereby maintaining broad adaptability while significantly simplifying the treatment regimen and improving ease of operation.
3Reliability
If conventional treatments are used for mitochondrial conditions, then basic therapeutic effect is achieved, but inflammatory and oxidative stress are not sufficiently reduced
Solution Approach 1:
The patent employs a composite material approach by formulating a combination of multiple urolithin compounds (A, B, C, D) that work synergistically to address both mitochondrial function enhancement and the reduction of harmful factors. This composite formulation provides superior efficacy in reducing inflammatory and oxidative stress compared to single compounds, while simultaneously improving mitochondrial function, thereby resolving the contradiction between therapeutic effect and harmful factor reduction.
Data Source
AI summary
The invention relates to compositions comprising urolithins with active agents, particularly compositions comprising urolithins and one or more ginseng-derived compounds or a ginseng extract; and/or one of more notoginseng-derived compounds or a notoginseng extract. The invention also relates to uses of such compositions, for use for the treatment or prevention of diseases, disorders and conditions, and for non-therapeutic uses.